文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症自身免疫性溶血性贫血在ICU:血浆置换是否有用?法国多中心回顾性研究

Severe autoimmune hemolytic anemia in ICU: a place for emergency plasma exchange? A French multicenter retrospective study.
PubMed 文献 · Crit Care · 2025-09-30
一句话结论重症自身免疫性溶血性贫血ICU死亡率17.6%,主要由器官功能障碍驱动;标准激素治疗和血浆置换与生存改善相关,但需前瞻性研究确认。

该多中心回顾性队列纳入2017至2024年巴黎公共医院网络15个ICU的148例次重症自身免疫性溶血性贫血溶血危象。ICU死亡率17.6%,年龄>60岁、肾脏替代治疗、机械通气和高剂量静脉甲泼尼龙为死亡危险因素,死亡主要由器官功能障碍而非贫血严重程度驱动。标准皮质激素治疗(1-2 mg/kg)与血浆置换均与生存改善相关,血浆置换的关联在倾向评分和IPTW调整后仍持续。作者认为血浆置换可能作为部分患者桥接免疫抑制治疗的手段,但需前瞻性研究确认。

要点

  • 重症自身免疫性溶血性贫血ICU死亡率17.6%,死亡主要由器官功能障碍驱动而非贫血严重程度。
  • 年龄>60岁、肾脏替代治疗、机械通气和高剂量静脉甲泼尼龙为ICU死亡危险因素。
  • 标准皮质激素治疗(1-2 mg/kg)与ICU生存改善相关(OR 0.19 [0.03-0.94],P=0.05)。
  • 血浆置换与ICU生存改善相关(OR 0.04 [0.004-0.4],P=0.008),倾向评分调整后OR 0.04 [0.001-0.39],IPTW调整后OR 0.13 [0.02-0.55]。
  • 作者认为血浆置换可能作为部分病例桥接免疫抑制治疗的手段,需前瞻性研究确认。

适用人群与场景

  • 2017至2024年巴黎公共医院网络15个ICU收治的148例次重症自身免疫性溶血性贫血溶血危象成人患者,入ICU中位年龄61岁(48-71),男性51%。
  • 入ICU中位血红蛋白5.2 g/dL(4.2-7.2)。

处置流程与药物剂量

  • 标准皮质激素治疗剂量为1-2 mg/kg,与ICU生存改善相关(OR 0.19 [0.03-0.94],P=0.05)。
  • 血浆置换与ICU生存改善相关,倾向评分调整后OR 0.04 [0.001-0.39](P=0.012),IPTW调整后OR 0.13 [0.02-0.55](P=0.011);作者认为其可能作为部分病例桥接免疫抑制治疗的手段。

红旗征与不能漏的情况

  • 年龄>60岁、需要肾脏替代治疗、需要机械通气、使用高剂量静脉甲泼尼龙为ICU死亡危险因素。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入15个ICU的148例次重症自身免疫性溶血性贫血溶血危象,入ICU中位年龄61岁(48-71),男性51%,入ICU中位血红蛋白5.2 g/dL(4.2-7.2),ICU死亡率17.6%。
  • ICU死亡危险因素包括年龄>60岁、肾脏替代治疗、机械通气和高剂量静脉甲泼尼龙;死亡主要由器官功能障碍而非贫血严重程度驱动。
  • 标准皮质激素治疗(1-2 mg/kg)与ICU生存改善相关(OR 0.19 [0.03-0.94],P=0.05);血浆置换与ICU生存改善相关(OR 0.04 [0.004-0.4],P=0.008),倾向评分调整后OR 0.04 [0.001-0.39](P=0.012),IPTW调整后OR 0.13 [0.02-0.55](P=0.011)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性;作者在结论中指出需前瞻性研究确认这些发现。

对床旁实践的改变

  • 对重症自身免疫性溶血性贫血ICU患者,器官功能障碍(如需肾脏替代治疗、机械通气)而非贫血严重程度是死亡的主要驱动因素。
  • 标准皮质激素治疗(1-2 mg/kg)与ICU生存改善相关。
  • 血浆置换与ICU生存改善相关,作者认为其可能作为部分病例桥接免疫抑制治疗的手段,需前瞻性研究确认。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Autoimmune hemolytic anemia (AIHA) is a rare but potentially life-threatening condition requiring intensive care unit (ICU) admission in severe cases. While corticosteroids and immunosuppressants are standard treatments, their delayed efficacy limits their utility in critical settings requiring rapid hemolysis control. Plasma exchange (PlEx) may offer a rapid intervention, but its effectiveness in severe AIHA remains uncertain. This study aims to assess the clinical characteristics, outcomes, and the potential benefit of PlEx in ICU cases with severe AIHA.

METHODS: We conducted a multicenter retrospective cohort study including patients with severe AIHA admitted to 15 ICUs within the Assistance Publique-Hôpitaux de Paris (AP-HP) network between 2017 and 2024. Clinical, biological, and therapeutic data were collected. A multivariate logistic regression model, an analysis adjusted on a propensity score (PS) and on inverse probability of treatment weighting (IPTW) were used to identify predictors of in-ICU mortality and evaluate the association between PlEx and in-ICU mortality.

RESULTS: One hundred forty-eight ICU stays involving severe AIHA hemolytic crises were analyzed. The median age at ICU admission was 61 {48-71} years, with a balanced sex ratio (51% male). Admission median hemoglobin was 5.2 g/dL {4.2-7.2} and in-ICU mortality was 17.6%. Risk factors for in-ICU mortality included age > 60 years, renal replacement therapy, mechanical ventilation, and high-dose intravenous methylprednisolone (HDIM). Therefore, ICU mortality was mainly driven by organ dysfunction rather than anemia severity. Standard corticosteroid therapy (1-2 mg/kg) (OR:0.19 [0.03-0.94], P = 0.05) and PlEx (OR:0.04 [0.004-0.4], P = 0.008) were associated with improved survival. The association between PlEx and outcome persisted after PS (OR: 0.04 [0.001-0.39]; P = 0.012) and IPTW (OR: 0.13 [0.02-0.55]; P = 0.011) adjustment.

CONCLUSION: In this large ICU cohort, severe AIHA was associated with high mortality, driven by organ failure rather than anemia severity. PlEx are associated with survival, suggesting its potential role as a bridge to immunosuppressive therapy in selected cases. Prospective studies are needed to confirm these findings.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Destival JB, Urbina T, Bougouin W, et al. Severe autoimmune hemolytic anemia in ICU: a place for emergency plasma exchange? A French multicenter retrospective study. Crit Care. 2025. PMID: 41029710. doi:10.1186/s13054-025-05601-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。